title: Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
abstract: Saroglitazar is a dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemia.
  
  
  OBJECTIVE
  The objective of this study was to evaluate the safety and efficacy of saroglitazar 4 mg once daily in clinical practice.
  
  
  METHODS
  This was an observational, multicenter, single-arm study. Patients with type 2 diabetes (with on-going antidiabetic medication), age above 18 years, and triglycerides ≥200 mg/dL were included.
  
  
  RESULTS
  A total 2804 patients with a mean duration of diabetes 6.29 yrs were included in this analysis. The baseline demographic profile was: mean age of 53 yrs, mean body weight 72.3 kg and mean BMI of 27 kg/m(2). 62.5% patients were male and 57.8% were reported to be on statin therapy at baseline. All 2804 patients were on antidiabetic medications with 15.4% patients on monotherapy and rest were on two or more than two antidiabetic medications at baseline. The baseline triglycerides and HbA1C values were 312.3 mg/dL and 8.3% respectively. At 3 months follow-up, use of saroglitazar 4 mg led to significant reduction in TG (35.8%), LDL-C (16.4%), total cholesterol (19%) and non-HDL-C (23.4%). Addition of saroglitazar to baseline antidiabetic medications showed a significant 0.9% absolute reduction in HbA1c with significant improvement in fasting and post prandial plasma glucose. No serious adverse events, alteration in liver or renal enzymes and edema or weight gain were reported.
  
  
  CONCLUSIONS
  Saroglitazar is a potential therapeutic option in type 2 diabetic patients with high TG levels, not controlled by statins, for comprehensive control of lipid and glycemic parameters with acceptable safety profile.
authors.affiliation: Professor & Ex HOD, Department of Medicine, D.Y. Patil University, CMD, Sadanand Healthy Living Center, Mumbai, India.
authors.forename: Sadanand R
authors.initials: SR
authors.lastname: Shetty
authors.affiliation: Professor (Cardiology), Department of Medicine, Vivekananda Institute of Medical Sciences, Kolkata, India.
authors.forename: Soumitra
authors.initials: S
authors.lastname: Kumar
authors.affiliation: Professor & HOD, Department of Endocrinology, Osmania Medical College, Hyderabad, India.
authors.forename: R P
authors.initials: RP
authors.lastname: Mathur
authors.affiliation: Associate Professor, UN Mehta Institute of Cardiology, BJ Medical College, Ahmedabad, India.
authors.forename: Kamal H
authors.initials: KH
authors.lastname: Sharma
authors.affiliation: Zydus Tower, Near Satellite Cross Road, Opposite Iscon Temple, Satellite, Ahmedabad, India. Electronic address: ashokd.jaiswal@zyduscadila.com.
authors.forename: Ashok D
authors.initials: AD
authors.lastname: Jaiswal
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D050171:Dyslipidemias / Q000097:blood / Q000150:complications* / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007194:India / Q000453:epidemiology; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010666:Phenylpropionates / Q000008:administration & dosage*; D015995:Prevalence; D011758:Pyrroles / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D008055:Lipids; D010666:Phenylpropionates; D011758:Pyrroles; C000588741:saroglitazar
keywords: Diabetic dyslipidemia; PPAR; Saroglitazar; Triglycerides
references.citation: Atherosclerosis. 2011 Jul;217(1):1
references.pmid: 21722901
references.citation: PLoS One. 2014 May 09;9(5):e96808
references.pmid: 24817067
references.citation: Endocr Pract. 2013 May-Jun;19(3):536-57
references.pmid: 23816937
references.citation: Endocr Pract. 2012 Mar-Apr;18(2):269-93
references.pmid: 22507559
references.citation: Lancet. 2014 Aug 16;384(9943):626-635
references.pmid: 25131982
references.citation: Lancet. 2004 Sep 11-17;364(9438):937-52
references.pmid: 15364185
references.citation: J Diabetes Sci Technol. 2014 Jan 16;8(1):132-141
references.pmid: 24876549
references.citation: Lipids. 2010 Oct;45(10):907-14
references.pmid: 20524075
references.citation: Diabetes Care. 2015 Jan;38 Suppl:S49-57
references.pmid: 25537708
references.citation: Nat Clin Pract Endocrinol Metab. 2009 Mar;5(3):150-9
references.pmid: 19229235
references.citation: Diabetes Technol Ther. 2014 Feb;16(2):63-71
references.pmid: 24138536
references.citation: Am J Manag Care. 2004 Feb;10(2 Pt 2):163-70
references.pmid: 15005509
references.citation: Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
references.pmid: 24222016
references.citation: N Engl J Med. 2014 Jul 3;371(1):32-41
references.pmid: 24941082
references.citation: N Engl J Med. 2010 Aug 12;363(7):692; author reply 694-5
references.pmid: 20701533